Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported EBITDA Margin of 5.7% for Q1 2026, up 200611.0% year-over-year from N/an in Q1 2025, and up 97.98% on a QoQ basis from 282.71% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 16 years of EBITDA Margin data on file, last reported at 5.7% in Q1 2026.
- Quarterly EBITDA Margin rose 200611.0% year-over-year to 5.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 37.69% (up 53011.0% YoY) and the FY2025 annual result came in at 101.26%, up 54323.0% from the prior year.
- EBITDA Margin improved to 5.7% in Q1 2026 per LXRX's latest filing, from 282.71% in the prior quarter.
- Across five years, EBITDA Margin topped out at 11.13% in Q2 2025 and bottomed at 31196.3% in Q3 2023.
- The 4-year median for EBITDA Margin is 2632.25% (2024), against an average of 5473.82%.
- The widest annual swing landed in 2024, when EBITDA Margin soared 2752378 bps; it then sank 15468 bps in 2025.
- Tracing LXRX's EBITDA Margin over 4 years: stood at 6476.76% in 2023, then surged by 98 bps to 128.03% in 2024, then tumbled by 121 bps to 282.71% in 2025, then surged by 98 bps to 5.7% in 2026.
- Per Business Quant, the three latest LXRX EBITDA Margin figures stand at 5.7% (Q1 2026), 282.71% (Q4 2025), and 89.73% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | -5.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.70% |
| Dec 31, 2025 | -282.71% |
| Sep 30, 2025 | -89.73% |
| Jun 30, 2025 | 11.13% |
| Mar 31, 2025 | -2,011.81% |
| Dec 31, 2024 | -128.03% |
| Sep 30, 2024 | -3,672.51% |
| Jun 30, 2024 | -3,252.70% |
| Mar 31, 2024 | -4,435.32% |
| Dec 31, 2023 | -6,476.76% |
| Sep 30, 2023 | -31,196.30% |
| Jun 30, 2023 | -14,145.43% |
| Dec 31, 2021 | 9,019.72% |
| Jun 30, 2021 | -7,725.21% |
| Mar 31, 2021 | -77,581.48% |
| Dec 31, 2020 | 23.30% |
| Jun 30, 2020 | -278,476.00% |
| Mar 31, 2020 | -823.04% |
| Dec 31, 2019 | -585.42% |
| Sep 30, 2019 | 76.77% |
| Jun 30, 2019 | -237.19% |
| Mar 31, 2019 | -891.84% |
| Dec 31, 2018 | -97.97% |
| Sep 30, 2018 | -391.17% |
| Jun 30, 2018 | -249.12% |
| Mar 31, 2018 | -165.49% |
| Dec 31, 2017 | -66.18% |
| Sep 30, 2017 | -110.47% |
| Jun 30, 2017 | -289.64% |
| Mar 31, 2017 | -194.63% |
| Dec 31, 2016 | -98.57% |
| Jun 30, 2016 | -189.52% |
| Mar 31, 2016 | -275.07% |
| Dec 31, 2015 | 67.94% |
| Sep 30, 2015 | -6,240.64% |
| Jun 30, 2015 | -7,446.54% |
| Mar 31, 2015 | -1,561.94% |
| Dec 31, 2014 | -13.96% |
| Sep 30, 2014 | -9,666.11% |
| Jun 30, 2014 | -3,851.04% |
| Mar 31, 2014 | -11,128.88% |
| Dec 31, 2013 | -1,237.59% |
| Sep 30, 2013 | -13,298.74% |
| Jun 30, 2013 | -13,593.93% |
| Mar 31, 2013 | -7,209.72% |
| Dec 31, 2012 | -11,408.72% |
| Sep 30, 2012 | -7,929.57% |
| Jun 30, 2012 | -13,012.06% |
| Mar 31, 2012 | -9,982.00% |
| Dec 31, 2011 | -9,871.14% |
| Sep 30, 2011 | -7,363.38% |
| Jun 30, 2011 | -4,794.05% |
| Mar 31, 2011 | -4,965.44% |
| Dec 31, 2010 | -1,789.70% |
| Sep 30, 2010 | -3,105.38% |
| Jun 30, 2010 | -1,952.47% |